Cancer examination method and examination kit
OwnerMotoharu SEIKI, Naohiko KOSHIKAWAinventors
Life of this patent
Estimating the term…
Abstract
An object of the present invention is to elucidate a molecular mechanism of ligand-independent activation of EphA2 in cancer cells, make EphA2 a more useful target in the treatment of cancer, and provide a cancer testing method and the like using the mechanism. The present invention provides, for example, a cancer testing method including a step of measuring an amount of an EphA2 protein fragment having a molecular weight of from 30 kDa to 80 kDa in a sample derived from a subject.
Claims17
A method of testing cancer, comprising a step of measuring an amount of a fragment of EphA2 protein having a molecular weight of from 30 kDa to 80 kDa in a sample derived from a subject.
A kit for testing cancer, comprising an antibody capable of detecting a fragment of EphA2 protein having a molecular weight of from 30 kDa to 80 kDa.
A method of screening an anticancer agent, comprising:
- culturing a cell expressing EphA2 under conditions where MT1-MMP processes EphA2,
- adding a test compound to a culture medium of the cell and incubating in the presence of MT1-MMP, and
- determining whether EphA2 is processed or not.
An anticancer agent comprising a double stranded RNA having any of the following sequences:
- siRNA #1
- S:
- (SEQ ID NO:
- 6)
- ggauggacacggagaauuutt
- AS:
- (SEQ ID NO:
- 7)
- aaauucuccguguccaucctt
- siRNA #2
- S:
- (SEQ ID NO:
- 8)
- gcgaugaagucuucacuuatt,
- AS:
- (SEQ ID NO:
- 9)
- uaagugaagacuucaucgctt,
- and
- siRNA #3
- S:
- (SEQ ID NO:
- 10)
- ggguagagacccugagacatt
- AS:
- (SEQ ID NO:
- 11)
- ugucucagggucucuaccctt;
- or a precursor thereof, or a nucleic acid encoding the RNA or precursor.
A method of treating cancer, comprising inhibiting expression or function of MT1-MMP.
Dependencies are inferred from the claim text.